BACKGROUND: Atrazine is the most heavily applied agricultural pesticide for crop production in the United States. Both animal and human studies have suggested that atrazine is possibly carcinogenic, but results have been mixed. We evaluated cancer incidence in atrazine-exposed pesticide applicators among 53,943 participants in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. METHODS: We obtained detailed pesticide exposure information using a self-administered questionnaire completed at the time of enrollment (1993-1997). Cancer incidence was followed through December 31, 2001. We used adjusted Poisson regression to calculate rate ratios (RRs) and 95% confidence intervals (CIs) of multiple types of cancer among atrazine exposed applicators. P(trend) values were calculated using atrazine exposure as a continuous variable, and all statistical tests were two-sided. Two exposure metrics were used: quartiles of lifetime days of exposure and quartiles of intensity-weighted lifetime days of exposure. RESULTS: 36,513 (68%) applicators reported ever using atrazine; exposure was not associated with overall cancer incidence. Comparisons of cancer incidence in applicators with the highest atrazine exposure and those with the lowest exposure, assessed by lifetime days (RR(LD)) and intensity-weighted lifetime days (RR(IWLD)) of exposure yielded the following results: prostate cancer, RR(LD) = 0.88, 95% CI = 0.63 to 1.23, P(trend) =.26, and RR(IWLD) = 0.89, 95% CI = 0.63 to 1.25, P(trend) =.35; lung cancer, RR(LD) = 1.91, 95% CI = 0.93 to 3.94, P(trend) =.08, and RR(IWLD) = 1.37, 95% CI = 0.65 to 2.86, P(trend) =.19; bladder cancer, RR(LD) = 3.06, 95% CI = 0.86 to 10.81, P(trend) =.18, and RR(IWLD) = 0.85, 95% CI = 0.24 to 2.94, P(trend) =.71; non-Hodgkin lymphoma, RR(LD) = 1.61, 95% CI = 0.62 to 4.16, P(trend) =.35, and RR(IWLD) = 1.75, 95% CI = 0.73 to 4.20, P(trend) =.14; and multiple myeloma, RR(LD) = 1.60, 95% CI = 0.37 to 7.01, P(trend) =.41, and RR(IWLD) = 2.17, 95% CI = 0.45 to 10.32, P(trend) =.21. CONCLUSIONS: Our analyses did not find any clear associations between atrazine exposure and any cancer analyzed. However, further studies are warranted for tumor types in which there was a suggestion of trend (lung, bladder, non-Hodgkin lymphoma, and multiple myeloma).
BACKGROUND:Atrazine is the most heavily applied agricultural pesticide for crop production in the United States. Both animal and human studies have suggested that atrazine is possibly carcinogenic, but results have been mixed. We evaluated cancer incidence in atrazine-exposed pesticide applicators among 53,943 participants in the Agricultural Health Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. METHODS: We obtained detailed pesticide exposure information using a self-administered questionnaire completed at the time of enrollment (1993-1997). Cancer incidence was followed through December 31, 2001. We used adjusted Poisson regression to calculate rate ratios (RRs) and 95% confidence intervals (CIs) of multiple types of cancer among atrazine exposed applicators. P(trend) values were calculated using atrazine exposure as a continuous variable, and all statistical tests were two-sided. Two exposure metrics were used: quartiles of lifetime days of exposure and quartiles of intensity-weighted lifetime days of exposure. RESULTS: 36,513 (68%) applicators reported ever using atrazine; exposure was not associated with overall cancer incidence. Comparisons of cancer incidence in applicators with the highest atrazine exposure and those with the lowest exposure, assessed by lifetime days (RR(LD)) and intensity-weighted lifetime days (RR(IWLD)) of exposure yielded the following results: prostate cancer, RR(LD) = 0.88, 95% CI = 0.63 to 1.23, P(trend) =.26, and RR(IWLD) = 0.89, 95% CI = 0.63 to 1.25, P(trend) =.35; lung cancer, RR(LD) = 1.91, 95% CI = 0.93 to 3.94, P(trend) =.08, and RR(IWLD) = 1.37, 95% CI = 0.65 to 2.86, P(trend) =.19; bladder cancer, RR(LD) = 3.06, 95% CI = 0.86 to 10.81, P(trend) =.18, and RR(IWLD) = 0.85, 95% CI = 0.24 to 2.94, P(trend) =.71; non-Hodgkin lymphoma, RR(LD) = 1.61, 95% CI = 0.62 to 4.16, P(trend) =.35, and RR(IWLD) = 1.75, 95% CI = 0.73 to 4.20, P(trend) =.14; and multiple myeloma, RR(LD) = 1.60, 95% CI = 0.37 to 7.01, P(trend) =.41, and RR(IWLD) = 2.17, 95% CI = 0.45 to 10.32, P(trend) =.21. CONCLUSIONS: Our analyses did not find any clear associations between atrazine exposure and any cancer analyzed. However, further studies are warranted for tumor types in which there was a suggestion of trend (lung, bladder, non-Hodgkin lymphoma, and multiple myeloma).
Authors: J H Mandel; M A Kelsh; P J Mink; D D Alexander; R M Kalmes; M Weingart; L Yost; M Goodman Journal: Occup Environ Med Date: 2006-04-27 Impact factor: 4.402
Authors: A Blair; D Sandler; K Thomas; J A Hoppin; F Kamel; J Coble; W J Lee; J Rusiecki; C Knott; M Dosemeci; C F Lynch; J Lubin; M Alavanja Journal: J Agric Saf Health Date: 2005-05
Authors: Dominik D Alexander; Douglas L Weed; Pamela J Mink; Meghan E Mitchell Journal: Int Arch Occup Environ Health Date: 2011-12-10 Impact factor: 3.015
Authors: Elizabeth M Ward; Paul A Schulte; Kurt Straif; Nancy B Hopf; Jane C Caldwell; Tania Carreón; David M DeMarini; Bruce A Fowler; Bernard D Goldstein; Kari Hemminki; Cynthia J Hines; Kirsti Husgafvel Pursiainen; Eileen Kuempel; Joellen Lewtas; Ruth M Lunn; Elsebeth Lynge; Damien M McElvenny; Hartwig Muhle; Tamie Nakajima; Larry W Robertson; Nathaniel Rothman; Avima M Ruder; Mary K Schubauer-Berigan; Jack Siemiatycki; Debra Silverman; Martyn T Smith; Tom Sorahan; Kyle Steenland; Richard G Stevens; Paolo Vineis; Shelia Hoar Zahm; Lauren Zeise; Vincent J Cogliano Journal: Environ Health Perspect Date: 2010-06-18 Impact factor: 9.031
Authors: Ola Landgren; Robert A Kyle; Jane A Hoppin; Laura E Beane Freeman; James R Cerhan; Jerry A Katzmann; S Vincent Rajkumar; Michael C Alavanja Journal: Blood Date: 2009-04-22 Impact factor: 22.113
Authors: Robin Taylor Wilson; Mark Donahue; Gloria Gridley; Johanna Adami; Laure El Ghormli; Mustafa Dosemeci Journal: Am J Ind Med Date: 2008-02 Impact factor: 2.214
Authors: Jennifer A Rusiecki; Rahulkumar Patel; Stella Koutros; Laura Beane-Freeman; Ola Landgren; Matthew R Bonner; Joseph Coble; Jay Lubin; Aaron Blair; Jane A Hoppin; Michael C R Alavanja Journal: Environ Health Perspect Date: 2008-11-10 Impact factor: 9.031